Douglas Miehm
Stock Analyst at RBC Capital
(3.42)
# 968
Out of 4,996 analysts
47
Total ratings
52.38%
Success rate
5.01%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNKD MannKind | Maintains: Outperform | $7 → $8 | $5.53 | +44.67% | 3 | Aug 26, 2025 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Outperform | $8 → $9 | $13.14 | -31.51% | 10 | Aug 1, 2025 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $8.5 → $10 | $6.48 | +54.32% | 20 | May 2, 2025 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $18 → $17 | $14.50 | +17.24% | 13 | Apr 4, 2025 | |
| ONCY Oncolytics Biotech | Maintains: Outperform | $6 → $5 | $1.29 | +287.60% | 1 | Mar 10, 2025 |
MannKind
Aug 26, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $5.53
Upside: +44.67%
Aurinia Pharmaceuticals
Aug 1, 2025
Maintains: Outperform
Price Target: $8 → $9
Current: $13.14
Upside: -31.51%
Bausch Health Companies
May 2, 2025
Maintains: Sector Perform
Price Target: $8.5 → $10
Current: $6.48
Upside: +54.32%
Bausch + Lomb
Apr 4, 2025
Maintains: Outperform
Price Target: $18 → $17
Current: $14.50
Upside: +17.24%
Oncolytics Biotech
Mar 10, 2025
Maintains: Outperform
Price Target: $6 → $5
Current: $1.29
Upside: +287.60%